Answers are grounded in this paper and cite their sources.
Phase I clinical trials demonstrate immune response boosting and favorable safety in humans, suggesting therapeutic potential for HIV-1 DNA vaccines.
Humoral and cellular immune responses have been produced by intramuscular vaccination with DNA plasmids expressing HIV-1 genes, suggesting possible immunotherapeutic and prophylactic value for these constructs. Vaccination with these constructs has decreased HIV-1 viral load in HIV-1-infected chimpanzees. In addition, naive (i.e. non-HIV-1-infected) chimpanzees were protected against a heterologous challenge with HIV-1. Ongoing phase I clinical trials show that therapeutic vaccinations indeed boost anti-HIV-1 immune responses in humans. A therapeutic phase I trial on humans with these constructs induced a good safety profile and also demonstrated an immunological potentiation. These findings indicate that further studies with these constructs in humans are warranted.
No takes yet. Share an insight, caveat, or question.
Ugen et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: